Global Finolimumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Finolimumab market size was valued at US$ 36.01 million in 2025 and is forecast to a readjusted size of US$ 317 million by 2032 with a CAGR of 28.3% during review period.
Finolimumab is a recombinant humanized anti-PD-1 monoclonal antibody developed by Sinocelltech. It specifically binds to the PD-1 receptor on the surface of T cells, blocks the PD-1/PD-L1 immunosuppressive pathway, relieves the inhibition of the body's immune system by tumor cells, and activates the endogenous anti-tumor immune response, thereby inhibiting tumor proliferation and metastasis. As a new generation of immune checkpoint inhibitor, this drug is mainly used for the treatment of solid tumors such as recurrent or metastatic squamous cell carcinoma of the head and neck and advanced hepatocellular carcinoma. It is characterized by high affinity, moderate half-life and controllable immune-related adverse reactions. It can be used alone or in combination with chemotherapy and targeted drugs, providing a long-acting and safe immunotherapy option for patients with advanced malignant tumors.In 2025, global Finolimumab (AnYouPing®) production reached approximately 12,000 vials
As a new generation of domestic PD‑1 inhibitor, Finolimumab occupies a unique position in the domestic immunotherapy market by virtue of its differentiated indication layout and clinical efficacy advantages. Its core strength lies in filling the gap of domestic PD‑1 in the first-line treatment of the full population with head and neck squamous cell carcinoma, while demonstrating excellent survival benefits in hepatocellular carcinoma, with clinical data significantly superior to traditional regimens. Faced with the intense competition and highly saturated domestic PD‑1 market between imported and domestic products, Finolimumab has strong potential for domestic substitution relying on localized R&D, clinical data more suitable for Chinese patients, and price advantages over imported drugs. Its inclusion in the national medical insurance catalogue has significantly improved accessibility and affordability, which will further drive the rapid growth of market penetration. In the future, its market expansion will focus on indication expansion, penetration into primary medical markets, and development of combination therapies. Meanwhile, it faces challenges such as medical insurance price reduction, rapid follow-up of competitors, and intensified price competition. It is necessary to consolidate and expand its market position through continuous clinical value establishment, academic promotion and optimization of commercialization strategies.
This report is a detailed and comprehensive analysis for global Finolimumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Finolimumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Finolimumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Finolimumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Finolimumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Finolimumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Finolimumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sinocelltech Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Finolimumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100 mg / 4 mL
200 mg / 8 mL
Market segment by Combination Therapy
Combination with Platinum-Based Chemotherapeutic Agents
Combination with Anti-Angiogenic Targeted Drugs
Market segment by Antibody Type
Monoclonal Antibody
Polyclonal Antibody
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Head and Neck Squamous Cell Carcinoma
Hepatocellular Carcinoma (HCC)
Non-Small Cell Lung Cancer (NSCLC)
Others
Major players covered
Sinocelltech Group
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Finolimumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Finolimumab, with price, sales quantity, revenue, and global market share of Finolimumab from 2021 to 2026.
Chapter 3, the Finolimumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Finolimumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Finolimumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Finolimumab.
Chapter 14 and 15, to describe Finolimumab sales channel, distributors, customers, research findings and conclusion.